Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.

Analysts anticipate Twist Bioscience to report an earnings per share (EPS) of $-0.46. Anticipation surrounds Twist Bioscience ...

Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 ...

Generic drugmaker Sandoz expects unbranded versions of Novo Nordisk's blockbuster diabetes drug Ozempic to launch in Canada ...

As Catalent sets up shop in a new headquarters and refines its corporate image under the ownership of Novo Holdings, the CDMO ...

A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse ...

In a surprise move, the FDA has named the longtime leader of its oncology department, Richard Pazdur, M.D., as the new ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

UniQure stock dropped after the FDA sent feedback on the company's pending treatment for Huntington's disease. Read more on ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Stifel 2025 Healthcare Conference November 11, 2025 10:00 AM ESTCompany ParticipantsOlivier Loeillot - President, CEO ...

The price of gold has rebounded over the past week after slumping for a few weeks following a series of record highs. Several ...